Finally, migration assays demonstrated that treatment with a TGF-β1 agonist enhanced the migratory ability of HCC cells, whereas USP4 knockdown inhibited this effect (Figs. 5F). This evidence concerns the gene TGFB1 and hepatocellular carcinoma.